In an attempt to globally block PI3K/AKT/MTORC signaling we tested the antileukemic potency of a novel pan class I PI3K and MTORC1 plus MTORC2 inhibitor, NVP-BGT226 [27], in comparison to a second dual inhibitor (NVP-BEZ235 [28]) currently widely under clinical investigation – including acute leukemia (European Clinical Trials Database number EUDRACT2011-005050-61). This evidence concerns the gene AKT1 and acute leukemia.